Swiss Life Asset Management Ltd Purchases 9,910 Shares of IDEXX Laboratories, Inc. $IDXX

Swiss Life Asset Management Ltd lifted its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 37.3% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 36,450 shares of the company’s stock after buying an additional 9,910 shares during the quarter. Swiss Life Asset Management Ltd’s holdings in IDEXX Laboratories were worth $24,660,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Virtus Advisers LLC purchased a new position in shares of IDEXX Laboratories in the third quarter worth $26,000. Park Place Capital Corp purchased a new position in shares of IDEXX Laboratories in the fourth quarter worth $29,000. J.Safra Asset Management Corp purchased a new position in shares of IDEXX Laboratories in the third quarter worth $31,000. Mowery & Schoenfeld Wealth Management LLC lifted its holdings in shares of IDEXX Laboratories by 58.8% in the fourth quarter. Mowery & Schoenfeld Wealth Management LLC now owns 54 shares of the company’s stock worth $37,000 after buying an additional 20 shares in the last quarter. Finally, Greykasell Wealth Strategies Inc. purchased a new position in shares of IDEXX Laboratories in the third quarter worth $35,000. Hedge funds and other institutional investors own 87.84% of the company’s stock.

Insider Buying and Selling at IDEXX Laboratories

In other news, EVP Michael G. Erickson sold 5,371 shares of the stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $627.38, for a total value of $3,369,657.98. Following the sale, the executive vice president owned 12,693 shares of the company’s stock, valued at approximately $7,963,334.34. This represents a 29.73% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Sophie V. Vandebroek sold 1,464 shares of the stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $628.62, for a total transaction of $920,299.68. Following the completion of the sale, the director directly owned 648 shares in the company, valued at approximately $407,345.76. This represents a 69.32% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 34,612 shares of company stock valued at $22,525,070. Corporate insiders own 0.79% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently commented on IDXX. Barclays lowered their target price on shares of IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating on the stock in a report on Thursday, February 5th. Citigroup began coverage on shares of IDEXX Laboratories in a report on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 target price on the stock. Wall Street Zen downgraded shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. BTIG Research lowered their target price on shares of IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating on the stock in a report on Tuesday, February 3rd. Finally, Weiss Ratings reissued a “hold (c+)” rating on shares of IDEXX Laboratories in a report on Monday, April 27th. Seven equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $751.00.

IDEXX Laboratories Stock Performance

IDEXX Laboratories stock opened at $532.00 on Tuesday. The company’s 50-day moving average price is $581.15 and its 200-day moving average price is $648.62. IDEXX Laboratories, Inc. has a twelve month low of $496.61 and a twelve month high of $769.98. The company has a quick ratio of 0.82, a current ratio of 1.12 and a debt-to-equity ratio of 0.19. The company has a market cap of $41.96 billion, a PE ratio of 39.18, a price-to-earnings-growth ratio of 3.26 and a beta of 1.58.

IDEXX Laboratories (NASDAQ:IDXX) last posted its earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share for the quarter, topping analysts’ consensus estimates of $3.41 by $0.06. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. The firm had revenue of $1.14 billion for the quarter, compared to the consensus estimate of $1.12 billion. During the same period in the previous year, the firm posted $2.91 EPS. The business’s quarterly revenue was up 14.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. On average, equities research analysts forecast that IDEXX Laboratories, Inc. will post 14.65 EPS for the current fiscal year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.